Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Jesus Delgado-Calle to Multiple Myeloma

This is a "connection" page, showing publications Jesus Delgado-Calle has written about Multiple Myeloma.

 
Connection Strength
  
 
 
2.176
  
  1. Sabol HM, Ashby C, Adhikari M, Anloague A, Kaur J, Khan S, Choudhury SR, Schinke C, Palmieri M, Barnes CL, Ambrogini E, Nookaew I, Delgado-Calle J. A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma. Haematologica. 2024 08 01; 109(8):2606-2618.
    View in: PubMed
    Score: 0.344
  2. Delgado-Calle J, Roodman GD. Doubling Down on Wnt Signaling to Overcome Myeloma Bone Disease. J Bone Miner Res. 2023 06; 38(6):812-813.
    View in: PubMed
    Score: 0.317
  3. Sabol HM, Amorim T, Ashby C, Halladay D, Anderson J, Cregor M, Sweet M, Nookaew I, Kurihara N, Roodman GD, Bellido T, Delgado-Calle J. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia. 2022 06; 28:100785.
    View in: PubMed
    Score: 0.293
  4. Sabol HM, Ferrari AJ, Adhikari M, Amorim T, McAndrews K, Anderson J, Vigolo M, Lehal R, Cregor M, Khan S, Cuevas PL, Helms JA, Kurihara N, Srinivasan V, Ebetino FH, Boeckman RK, Roodman GD, Bellido T, Delgado-Calle J. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer Res. 2021 10 01; 81(19):5102-5114.
    View in: PubMed
    Score: 0.279
  5. McDonald MM, Delgado-Calle J. Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease. Curr Osteoporos Rep. 2017 12; 15(6):532-541.
    View in: PubMed
    Score: 0.217
  6. Delgado-Calle J, Anderson J, Cregor MD, Condon KW, Kuhstoss SA, Plotkin LI, Bellido T, Roodman GD. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017 12; 31(12):2686-2694.
    View in: PubMed
    Score: 0.209
  7. Delgado-Calle J, Anderson J, Cregor MD, Hiasa M, Chirgwin JM, Carlesso N, Yoneda T, Mohammad KS, Plotkin LI, Roodman GD, Bellido T. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma. Cancer Res. 2016 Mar 01; 76(5):1089-100.
    View in: PubMed
    Score: 0.191
  8. Delgado-Calle J, Bellido T, Roodman GD. Role of osteocytes in multiple myeloma bone disease. Curr Opin Support Palliat Care. 2014 Dec; 8(4):407-13.
    View in: PubMed
    Score: 0.176
  9. Marino S, Petrusca DN, Bishop RT, Anderson JL, Sabol HM, Ashby C, Layer JH, Cesarano A, Dav? UP, Perna F, Delgado-Calle J, Chirgwin JM, Roodman GD. Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma. Haematologica. 2024 05 01; 109(5):1501-1513.
    View in: PubMed
    Score: 0.084
  10. Mulcrone PL, Edwards SKE, Petrusca DN, Haneline LS, Delgado-Calle J, Roodman GD. Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23. Sci Rep. 2020 10 14; 10(1):17319.
    View in: PubMed
    Score: 0.066
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.